BEPACT- Lung: Impact of Patient Characteristics on Pneumo-oncologists Non Small Cell Lung Cancer (NSCLC) Systemic Treatment Decision in Belgium

Completed

Brief Summary: The treatment landscape of metastatic non small cell lung cancer (NSCLC) is rapidly evolving. There are new diagnostic and treatment options available in the coming months and years.

New combination treatments will give different solutions to pneumo-oncologists who might be guided by certain patient and tumor characteristics.

The link between patient and tumor characteristics in untreated stage IV non small cell lung cancer (NSCLC) patients and systemic treatment needs further investigation, allowing the identification of possible treatment issues, data gaps and/or areas of improvement.

Detailed Description: This is a multicenter, non-interventional, cross-sectional study. Consecutive patients with metastatic stage IV non small cell lung cancer (NSCLC) selected for systemic treatment or best supportive care will be included in the trial at the time the patient signed the informed consent form (ICF). Patients that were selected for systemic treatment, should have received at least their first dose and a maximum of one cycle of the same treatment.

The pneumo-oncologist that treats the patient will fill in the CRF, indicating the systemic treatment option and the link with the variable categories that impacted the choice for a systemic treatment option.

Recruitment & Eligibility

Inclusion Criteria

Have voluntarily agreed to participate by giving written informed consent/assent for the trial.
Have a histologically or cytologically confirmed diagnosis of stage IV non-small cell lung cancer (NSCLC) on first-line (1L) systemic treatment.
Have received at least their first dose of the selected systemic treatment and a maximum of 1 cycle of the same treatment. Patients that were selected to receive best supportive care will not have to comply to this inclusion criterion.
Be ≥ 18 years of age on day of signing informed consent.

Exclusion Criteria

Has received prior systemic treatment for their metastatic non-small cell lung cancer (NSCLC) before the first dose of trial treatment. However, subjects who received adjuvant or neoadjuvant therapy during an earlier stage of their disease, but evolved to stage IV, are eligible.
Tyrosine kinase inhibitor (TKI) selected as first-line systemic treatment.
Is participating in an interventional trial or medical need program.

Arm && Interventions

Group	Intervention	Description
Primary study group	None - Common practice	Stage IV untreated NSCLC

Primary Outcome Measures

Name	Time	Method
The Study Outcome is Defined as the Systemic Treatment Choice.	during visits 1 and 2, up to approximately 3 weeks	Systemic treatment choices are defined as : 1. Chemotherapy (chemo) 2. Immunotherapy (IO) 3. immuno combined therapies (IO+IO) 4. IO+chemo 5. IO+bevacizumab+chemo (IO+bev+chemo) 6. best supportive care (BSC). There is no exposure in this study.

Secondary Outcome Measures

Name	Time	Method

Locations (21): Imelda Ziekenhuis
🇧🇪
Bonheiden, Belgium
St Trudo Ziekenhuis
🇧🇪
Sint-Truiden, Belgium
CH de Charleroi
🇧🇪
Charleroi, Belgium
CH Jolimont
🇧🇪
Haine-Saint-Paul, Belgium
Jessa Ziekenhuis
🇧🇪
Hasselt, Belgium
UZ Gent
🇧🇪
Gent, Belgium
Az Groeninghe Kortrijk
🇧🇪
Kortrijk, Belgium
CHU UCL Namur, site Godinne
🇧🇪
Namur, Belgium
Clinique St-Pierre Ottignies
🇧🇪
Ottignies, Belgium
AZ Turnhout
🇧🇪
Turnhout, Belgium
CHU de Liège
🇧🇪
Liège, Belgium
AZ Delta
🇧🇪
Roeselare, Belgium
Cliniques Universitaires Saint-Luc UCL Bruxelles
🇧🇪
Brussels, Belgium
UZ Leuven
🇧🇪
Leuven, Belgium
CHR Citadelle
🇧🇪
Liège, Belgium
AZ St Nikolaas
🇧🇪
Saint-Nicolas, Belgium
UZA
🇧🇪
Antwerpen, Belgium
ZNA Middelheim
🇧🇪
Antwerpen, Belgium
UZ Brussel
🇧🇪
Brussel, Belgium
CHIREC
🇧🇪
Bruxelles, Belgium
CHC Liège
🇧🇪
Liège, Belgium